Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

Daniel A. Sweeney; Bonifride Tuyishimire; Neera Ahuja; John H. Beigel; Tatiana Beresnev; Valeria D. Cantos; Jose G. Castro; Stuart H. Cohen; Kaitlyn Cross; Lori E. Dodd; Nathan Erdmann; Monica Fung; Varduhi Ghazaryan; Sarah L. George; Kevin A. Grimes; Noreen A. Hynes; Kathleen G. Julian; Sheetal Kandiah; Hannah Jang Kim; Corri B. Levine; David A. Lindholm; David C. Lye; Ryan C. Maves; Myoung Don Oh; Catharine Paules; Rekha R. Rapaka; Willam R. Short; Kay M. Tomashek; Cameron R. Wolfe; Andre C. Kalil

doi:10.1093/ofid/ofad205

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

Daniel A. Sweeney, Bonifride Tuyishimire, Neera Ahuja, John H. Beigel, Tatiana Beresnev, Valeria D. Cantos, Jose G. Castro, Stuart H. Cohen, Kaitlyn Cross, Lori E. Dodd, Nathan Erdmann, Monica Fung, Varduhi Ghazaryan, Sarah L. George, Kevin A. Grimes, Noreen A. Hynes, Kathleen G. Julian, Sheetal Kandiah, Hannah Jang Kim, Corri B. LevineDavid A. Lindholm, David C. Lye, Ryan C. Maves, Myoung Don Oh, Catharine Paules, Rekha R. Rapaka, Willam R. Short, Kay M. Tomashek, Cameron R. Wolfe, Andre C. Kalil

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

Original language	English (US)
Article number	ofad205
Journal	Open Forum Infectious Diseases
Volume	10
Issue number	5
DOIs	https://doi.org/10.1093/ofid/ofad205
State	Published - May 1 2023
Externally published	Yes

Keywords

COVID-19
baricitinib
secondary infections

ASJC Scopus subject areas

Oncology
Infectious Diseases

Access to Document

10.1093/ofid/ofad205

Cite this

Sweeney, D. A., Tuyishimire, B., Ahuja, N., Beigel, J. H., Beresnev, T., Cantos, V. D., Castro, J. G., Cohen, S. H., Cross, K., Dodd, L. E., Erdmann, N., Fung, M., Ghazaryan, V., George, S. L., Grimes, K. A., Hynes, N. A., Julian, K. G., Kandiah, S., Kim, H. J., ... Kalil, A. C. (2023). Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections. Open Forum Infectious Diseases, 10(5), Article ofad205. https://doi.org/10.1093/ofid/ofad205

Sweeney, DA, Tuyishimire, B, Ahuja, N, Beigel, JH, Beresnev, T, Cantos, VD, Castro, JG, Cohen, SH, Cross, K, Dodd, LE, Erdmann, N, Fung, M, Ghazaryan, V, George, SL, Grimes, KA, Hynes, NA, Julian, KG, Kandiah, S, Kim, HJ, Levine, CB, Lindholm, DA, Lye, DC, Maves, RC, Oh, MD, Paules, C, Rapaka, RR, Short, WR, Tomashek, KM, Wolfe, CR & Kalil, AC 2023, 'Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections', Open Forum Infectious Diseases, vol. 10, no. 5, ofad205. https://doi.org/10.1093/ofid/ofad205

@article{d8c70c9d62c94a8dbd979c2011069bc2,

title = "Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections",

abstract = "We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50\% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.",

keywords = "COVID-19, baricitinib, secondary infections",

author = "Sweeney, \{Daniel A.\} and Bonifride Tuyishimire and Neera Ahuja and Beigel, \{John H.\} and Tatiana Beresnev and Cantos, \{Valeria D.\} and Castro, \{Jose G.\} and Cohen, \{Stuart H.\} and Kaitlyn Cross and Dodd, \{Lori E.\} and Nathan Erdmann and Monica Fung and Varduhi Ghazaryan and George, \{Sarah L.\} and Grimes, \{Kevin A.\} and Hynes, \{Noreen A.\} and Julian, \{Kathleen G.\} and Sheetal Kandiah and Kim, \{Hannah Jang\} and Levine, \{Corri B.\} and Lindholm, \{David A.\} and Lye, \{David C.\} and Maves, \{Ryan C.\} and Oh, \{Myoung Don\} and Catharine Paules and Rapaka, \{Rekha R.\} and Short, \{Willam R.\} and Tomashek, \{Kay M.\} and Wolfe, \{Cameron R.\} and Kalil, \{Andre C.\}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2023",

month = may,

day = "1",

doi = "10.1093/ofid/ofad205",

language = "English (US)",

volume = "10",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

AU - Sweeney, Daniel A.

AU - Tuyishimire, Bonifride

AU - Ahuja, Neera

AU - Beigel, John H.

AU - Beresnev, Tatiana

AU - Cantos, Valeria D.

AU - Castro, Jose G.

AU - Cohen, Stuart H.

AU - Cross, Kaitlyn

AU - Dodd, Lori E.

AU - Erdmann, Nathan

AU - Fung, Monica

AU - Ghazaryan, Varduhi

AU - George, Sarah L.

AU - Grimes, Kevin A.

AU - Hynes, Noreen A.

AU - Julian, Kathleen G.

AU - Kandiah, Sheetal

AU - Kim, Hannah Jang

AU - Levine, Corri B.

AU - Lindholm, David A.

AU - Lye, David C.

AU - Maves, Ryan C.

AU - Oh, Myoung Don

AU - Paules, Catharine

AU - Rapaka, Rekha R.

AU - Short, Willam R.

AU - Tomashek, Kay M.

AU - Wolfe, Cameron R.

AU - Kalil, Andre C.

PY - 2023/5/1

Y1 - 2023/5/1

N2 - We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

AB - We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.

KW - COVID-19

KW - baricitinib

KW - secondary infections

UR - https://www.scopus.com/pages/publications/85160710570

UR - https://www.scopus.com/inward/citedby.url?scp=85160710570&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofad205

DO - 10.1093/ofid/ofad205

M3 - Article

C2 - 37206623

AN - SCOPUS:85160710570

SN - 2328-8957

VL - 10

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 5

M1 - ofad205

ER -

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this